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Dantrolene, a Therapeutic Agent for Malignant
Hyperthermia, Markedly Improves the Function of
Failing Cardiomyocytes by Stabilizing Interdomain
Interactions Within the Ryanodine Receptor
Shigeki Kobayashi, MD, PHD,* Masafumi Yano, MD, PHD,* Takeshi Suetomi, MD,*
Makoto Ono, MD,* Hiroki Tateishi, MD,* Mamoru Mochizuki, MD, PHD,* Xiaojuan Xu, MD,*
Hitoshi Uchinoumi, MD,* Shinichi Okuda, MD, PHD,* Takeshi Yamamoto, MD, PHD,*
Noritaka Koseki, BS,† Hiroyuki Kyushiki, PHD,† Noriaki Ikemoto, PHD,‡§
Masunori Matsuzaki, MD, PHD*
Yamaguchi and Tokushima, Japan; and Watertown and Boston, Massachusetts
Objectives We sought to investigate the effect of dantrolene, a drug generally used to treat malignant hyperthermia, on the
Ca2 release and cardiomyocyte function in failing hearts.
Background The N-terminal (N: 1–600) and central (C: 2000–2500) domains of the ryanodine receptor (RyR) harbor many
mutations associated with malignant hyperthermia in skeletal muscle RyR (RyR1) and polymorphic ventricular
tachycardia in cardiac RyR (RyR2). There is strong evidence that interdomain interaction between these regions
plays an important role in the mechanism of channel regulation.
Methods Sarcoplasmic reticulum vesicles and cardiomyocytes were isolated from the left ventricular muscles of dogs (normal
or rapid ventricular pacing for 4 weeks), for Ca2 leak, transient, and spark assays. To assess the zipped or unzipped
state of the interacting domains, the RyR was labeled fluorescently with methylcoumarin acetate in a site-directed
manner. We used a quartz-crystal microbalance technique to identify the dantrolene binding site within the RyR2.
Results Dantrolene specifically bound to domain 601–620 in RyR2. In the sarcoplasmic reticulum isolated from pacing-
induced failing dog hearts, the defective interdomain interaction (domain unzipping) had already occurred, caus-
ing spontaneous Ca2 leak. Dantrolene suppressed both domain unzipping and the Ca2 leak, demonstrating
identical drug concentration-dependence (IC50  0.3 mol/l). In failing cardiomyocytes, both diastolic Ca
2
sparks and delayed afterdepolarization were observed frequently, but 1 mol/l dantrolene inhibited both events.
Conclusions Dantrolene corrects defective interdomain interactions within RyR2 in failing hearts, inhibits spontaneous Ca2
leak, and in turn improves cardiomyocyte function in failing hearts. Thus, dantrolene may have a potential to
treat heart failure, specifically targeting the RyR2. (J Am Coll Cardiol 2009;53:1993–2005) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.065r
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Che skeletal muscle type-1 and cardiac type-2 ryanodine
eceptors (RyR1 and RyR2, respectively) are intracellular
hannels that mediate Ca2 release from the sarcoplasmic
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ccepted January 19, 2009.eticulum (SR). More than 70 point mutations in RyR1
ave been reported to cause malignant hyperthermia (MH)
nd central core disease, both of which are potentially lethal
enetic disorders of skeletal muscle (1). As widely recog-
ized, MH mutations are not randomly distributed along
See page 2006
he RyR1 sequence. The majority of them are localized in 2
estricted regions: the N-terminal (Cys35-Arg614), and the
entral (Asp2129-Arg2458) domains, whereas a third,
-terminal region (Ile3916-Gly4942) contains fewer MH
utations (1). All of the RyR1 Ca2-release channels with
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Diastolic Ca2 Spark and Ryanodine Receptor May 26, 2009:1993–2005MH mutations are characterized
by a leaky SR Ca2 channel (1,2).
On the basis of the distribution
of these mutations, Yamamoto
et al. (3,4) proposed the hypothesis
that the interactions between the
N-terminal domain and the cen-
tral domain of RyR1 are involved
in Ca2 channel regulation as an
intrinsic regulator of the Ca2
channel and that these interacting
domains comprise a “domain
switch.” According to this hypoth-
esis, in the resting or nonactivated
state, the N-terminal and central
domains make close contact at sev-
eral subdomains (domain zipping).
The conformational constraints
imparted by the “zipped” con-
figuration of these 2 domains
tabilize and maintain the closed state of Ca2 channel.
timulation via excitation-contraction coupling or pharma-
ological agents weakens these critical interdomain contacts,
esulting in a reduction of conformational constraints (do-
ain unzipping), thereby lowering the energy barrier for
a2 channel opening. Weakening of these interdomain
nteractions may also occur via mutation or with the use of
ynthetic domain peptides.
To date, more than 60 RyR2 missense mutations have
een found to be linked with 2 inherited forms of sudden
ardiac death, that is, catecholaminergic polymorphic ven-
ricular tachycardia (CPVT), and arrhythmogenic right
entricular cardiomyopathy type 2 (ARVC2) (1). All RyR2
utations cluster into 3 regions of the channel that corre-
pond to the 3 MH/central core disease mutation regions
N-terminal domain, central domain, and channel-forming
omain) of RyR1.
Particularly, some mutations of RyR2, which have been
eported in cardiac disease patients, are located in the
egions corresponding to the skeletal N-terminal and central
omains harboring most of the MH mutations that cause an
ncreased Ca2 leak (5). This finding suggests that RyR2
hares a common domain-mediated channel regulation
echanism with RyR1 and that the increased Ca2 leak of
iseased RyR2 channels may be attributable to defective
odes of interdomain interaction. We recently reported
hat the defective interdomain interaction within the RyR2
namely, domain unzipping) destabilizes the channel gating
f the RyR2, associated with FK506 binding protein 12.6
issociation from RyR2 and Ca2 leak, causing contractile
ysfunction of cardiomyocyte (6). On the basis of these
ndings, we have proposed that the weakened interdomain
nteraction is one of the key mechanisms underlying the
athogenesis of ARVC2, CPVT, and heart failure and that
ormal operation of the domain switch is essential for
Abbreviations
and Acronyms
ARVC2  arrhythmogenic
right ventricular
cardiomyopathy type 2
CPVT  catecholaminergic
polymorphic ventricular
tachycardia
DAD  delayed
afterdepolarization
LV  left ventricle/
ventricular
MH  malignant
hyperthermia
QCM  quartz crystal
microbalance
RyR  ryanodine receptor
SR  sarcoplasmic
reticulumroper function of both RyR1 and RyR2 channels. zPaul-Pletzer et al. (7) have identified the dantrolene-
inding site within RyR1 as Leu590-Cys609 (named DP1) by
sing [3H]azidodantrolene, a pharmacologically active pho-
oaffinity analog of dantrolene. Recently, we demonstrated a
ovel mechanism by which dantrolene improves the hyper-
ensitization of channel gating to Ca2 observed in MH
hannels (8). Upon adding dantrolene to defective RyR1
a2 release channel mimicking MH, we found dantrolene
o produce a local conformational change, resulting in
einforcement of the interdomain interactions (8).
Because the amino acid sequence of the DP1 region is
xactly identical between RyR1 and RyR2, we hypothesized
hat dantrolene would be equally effective in correcting the
efective interdomain interaction in failing hearts. Here we
eport that dantrolene in fact corrects defective interdomain
nteraction within RyR2, inhibits Ca2 leak, and improves
ardiomyocyte function in failing hearts.
ethods
aterials. Dantrolene was purchased from Sigma Chem-
cal Co. (St. Louis, Missouri).
nimal disease model. In beagles, heart failure was
nduced by chronic rapid right ventricular pacing (Online
ppendix).
reparation of SR vesicles. We prepared SR vesicles from
ormal or 4-week paced failing left ventricles (LVs) ob-
ained from dogs, as described previously (9).
eptides used and peptide synthesis. Domain peptides
DPc10), corresponding to amino acids Gly2460-Pro2495 of
yR2, were synthesized and used for analysis of domain–
omain interaction within RyR2 (Online Appendix).
onstruction and expression of RyR2 fragments. The
eptides corresponding to various regions of RyR2 (1–610,
94–1000, 741–1260, 1245–1768, 1741–2270, 1981–2520,
nd 2234–2750) were amplified via polymerase chain reac-
ion (Online Appendix).
uartz crystal microbalance (QCM) measurements. Bind-
ng of dantrolene to RyR2 fragments was detected with the use
f a 27-MHz QCM (Initium, Inc., Tokyo, Japan) (Online
ppendix).
a2 uptake and leak assays. Ca2 uptake and the
ollowing Ca2 leak assays were conducted as described
reviously (9).
ite-directed fluorescent labeling of the RyR2. Specific
uorescent labeling of the RyR2 moiety of the SR mem-
rane was performed with the cleavable hetero-bifunctional
ross-linking reagent sulfosuccinimidyl 3-([2-(7-azido-4-
ethylcoumarin-3-acetamido) ethyl] dithio) propionate
rom Pierce (now Thermo Scientific, Rockford, Illinois),
ith DPc10 as a site-specific carrier following the site-
irected fluorescent labeling method (6).
luorescence quenching of the methylcoumarin acetate
uorescence attached to the DPc10 binding site. The
ipped and unzipped states of RyR were evaluated by
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May 26, 2009:1993–2005 Diastolic Ca2 Spark and Ryanodine Receptorhemical quencher analysis, as described previously (Online
ppendix) (4,6,8).
solation of cardiac cardiomyocytes. Cardiomyocytes were
solated from the LV free wall of normal or 4-week paced
ailing dogs, as described previously (Online Appendix) (6).
ell shortening and Ca2 transient measurement. Mea-
urements of cardiomyocyte cell shortening and intracellular
a2 were performed with fura-2 acetoxymethyl ester, as
escribed previously (Online Appendix) (6).
nalysis of Ca2 sparks with laser scanning confocal
icroscopy. Ca2 sparks were measured on a laser scan-
ing confocal microscope (Online Appendix).
easurement of membrane potential with laser scanning
onfocal microscopy. Measurements of membrane poten-
ial were performed on a laser scanning confocal microscope
ollowing the same protocol for the measurement of Ca2
parks (Online Appendix).
tatistics. The unpaired t test was used for statistical
omparison of data between the 2 states. We also used
nalysis of variance for repeated measures with a post-hoc
cheffe test for statistical comparison of concentration-
ependent data. Data are expressed as mean  SD. We
ccepted a value of p  0.05 as statistically significant.
esults
ffect of dantrolene on in vivo cardiac function. In the
antrolene-treated dogs with long-term right ventricular pac-
ng, both LV end-diastolic and -systolic diameters were smaller
han in dantrolene-untreated dogs, and fractional shortening
as significantly improved (Table 1, Fig. 1). This result
ndicates that the development of heart failure by pacing was
ttenuated by the treatment with dantrolene.
pecific binding of dantrolene to domain 601–620 of
yR2. Dantrolene was previously reported to bind to the
omain Leu590-Cys609 in the case of RyR1 (7). We inves-
igated whether dantrolene also binds to the corresponding
omain 601–620 of RyR2 by using a quartz crystal mi-
robalance technique (a highly sensitive mass-measuring
echnique). To identify the dantrolene-binding region, we
creened several recombinant fragments corresponding to
arious regions covering the area from the N-terminus to
emodynamic Data
Table 1 Hemodynamic Data
HR (beats/min) SBP (mm Hg)
Untreated (n  6)
Pre-pacing 116 12 130 16
1-week pacing 119 13 116 19
4-week pacing 121 14 120 11
Dantrolene-treated (n  4)
Pre-pacing 115 7 129 5
1-week pacing 119 2 123 6
4-week pacing 116 7 127 10
ach data point represents the mean SD. The number of experiments is shown in parentheses. A
re-pacing, †p  0.05 versus 1-week pacing (untreated), ‡p  0.05 versus 4-week pacing (untrea
DBP diastolic blood pressure; HR heart rate; LVDd left ventricular end-diastolic diameter; LVDs
lood pressure.esidue 2750, which include both of the aforementioned
ritical regulatory domains (N-terminal [1–600] and central
2000–2500] domains). Figure 2A shows the gel image of
hese recombinant fragments. As shown in Figure 2B, of all
ecombinant fragments we tested, only the fragment494–1000
howed the signal of dantrolene binding.
To test the hypothesis that RyR2 and RyR1 share the
dentical dantrolene binding sequence (as discussed in the
ntroduction section), DP601–620 (a synthetic peptide, de-
cribed previously, corresponding to DP1) was subjected to the
CM binding assay. As shown in the QCM recording of
igure 2C, there was a rapid binding of dantrolene to
P601–620. There was no detectable drug binding to the central
omain peptide: DPc10 (2460–2495) and to the N-terminal
omain peptide: DP163–195. As shown in Figure 2D, the
inding of dantrolene to fragment494–1000 or DP601–620 was
bolished in the copresence of excess dantrolene (30 mol/l).
antrolene inhibited both DPc10-induced Ca2 leak
rom the normal SR and spontaneous Ca2 leak from
he failing SR. The addition of 0.3 mol/l thapsigargin
o normal SR vesicles at a steady-state of adenosine
Figure 1 Effects of Dantrolene on Cardiac Function
Representative M-mode echocardiogram: pre-pacing and 1 and 4 weeks’ pacing.
P (mm Hg) LVDd (mm) LVDs (mm) LVFS (%)
81 5 31.1 2.1 20.5 2.8 34.6 7.3
82 5 36.7 2.1* 29.7 1.7* 19.0 3.6*
83 10 39.6 1.4* 34.4 1.6* 13.0 2.8*
84 5 31.2 1.6 20.4 2.1 34.8 6.4
80 9 32.0 1.8† 23.8 0.5*† 25.6 5.5†
85 6 35.0 2.3*‡ 27.8 2.2*‡ 20.6 6.2*‡
red t test was used to determine the statistical significance of the data (p value). *p 0.05 versusDB
n unpai
ted).left ventricular end-systolic diameter; LVFS left ventricular fractional shortening; SBP systolic
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Diastolic Ca2 Spark and Ryanodine Receptor May 26, 2009:1993–2005riphosphate-dependent Ca2 uptake produced little Ca2
eak, whereas the addition of 100 mol/l DPc10 together
ith 0.3 mol/l thapsigargin produced a pronounced leak.
owever, the Ca2 leak was almost completely suppressed
y 1 mol/l dantrolene (Fig. 3A). In failing SR, the addition
f 0.3 mol/l thapsigargin produced spontaneous Ca2 leak.
antrolene (1 mol/l) abolished the spontaneous Ca2 leak
hat otherwise would have occurred in the failing SR (Fig. 3A).
As shown in Figure 3B, the concentration dependence of
antrolene inhibition of DPc10-induced Ca2 leak in
Figure 2 Identification of the Dantrolene Binding Site Within R
(A) Gel image of the recombinant fragments corresponding to various regions cove
trolene binding site within the ryanodine receptor (RyR)2 with recombinant RyR2 fr
trolene was immobilized on the sensor chip surface, as described in the Methods
RyR2 fragments to dantrolene fixed on the sensor chip. Note that DP601–620 and R
presence of excess added dantrolene (D). Continued on next pageormal SR occurs in the concentration range of 0.1 to 1.0 emol/l, with the concentration of a half-maximal inhibition
IC50) of 0.3 mol/l. The concentration dependence and
C50 (0.3 mol/l) of dantrolene inhibition of the spontane-
us Ca2 leak in failing SR (Fig. 3C) are identical to those
f DPc10-induced Ca2 leak in the normal SR. We also
valuated the effect of dantrolene on Ca2 leak induced by
rotein kinase A phosphorylation of RyR2 (by cyclic aden-
sine monophosphate [cAMP]) (Fig. 3D). In the presence
f 1 mol/l dantrolene, cAMP-induced Ca2 leak was
ompletely inhibited. Dantolene (0.1 to 1 mol/l) had no
e area from the N-terminus to residue 2750. (B to D). Screening of the dan-
ts and synthetic peptides with the use of quartz-crystal microbalance. Dan-
n. The traces represent the time course of the binding of various peptides or
ragment 494–1000 specifically bound to the dantrolene (B and C) but not in theyR2
ring th
agmen
sectio
yR2 fffect on the Ca2 uptake time course (data not shown).
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May 26, 2009:1993–2005 Diastolic Ca2 Spark and Ryanodine Receptorantrolene reversed an abnormal domain unzipping of
he domain switch. To investigate the effect of dantrolene
n the mode of interdomain interaction between the
-terminal domain and the central domain (2 regulatory
omains of the domain switch; for more details, see the
ntroduction section), we used the methylcoumarin acetate
uorescence quenching technique we developed to deter-
ine the extent of unzipping of the domain switch (see the
ethods section). The slope of the plot, which is equal to
he Stern-Volmer quenching constant (KQ), is a measure of
he degree of domain unzipping.
As shown in our previous report (6), KQ increased with
ncreasing concentrations of DPc10 and leveled off at
pproximately 100 mol/l peptide. In the experiment
hown in Figure 4A, we investigated the effect of in-
reased concentrations of dantrolene on the KQ that had
eached a maximal level by 100 mol/l peptide. As shown
n Figure 4B, the K=Q/KQ value (where K=Q is the
uenching constant in the DPc10-treated SR and KQ is
he quenching constant in the untreated control SR) was
educed with an increase of dantrolene concentration,
nd at concentrations 1 mol/l it reached the control
evel (K=Q/KQ  1).
Importantly, the IC50 (0.3 mol/l) of dantrolene inhibi-
ion of domain unzipping shown here is identical to that of
Figure 2 Continuedantrolene inhibition of DPc10-induced Ca2 leak shown rn Figure 3B. Dantrolene had no appreciable effect on KQ
nless DPc10 was added (Fig. 4B). This finding suggests
hat in the normal SR the domain switch is in a fully zipped
tate. In contrast, the KQ value of failing SR was comparable
o the value of normal SR that had been treated with 100
mol/l DPc10, suggesting that in the failing RyR2 the
omain switch had already been unzipped. Dantrolene
educed KQ with a concentration dependence identical to
hat we have observed in the DPc10-added normal SR
Figs. 4C and 4D). Here again, the IC50 value (0.3 mol/l)
f dantrolene inhibition of domain unzipping is identical
ith that of spontaneous Ca2 leak in failing SR. These
esults indicate that dantrolene reverses domain unzipping
nd restabilizes the zipped configuration of the domain
witch, thereby inhibiting Ca2 leak.
ffects of dantrolene on Ca2 transient, cell shortening,
a2 spark, and membrane potential of normal and failing
ardiomyocytes. To investigate the effect of dantrolene on the
solated normal and failing cardiomyocytes, we measured both
a2 transient and cell shortening simultaneously in these
ardiomyocytes. As shown in Figure 5A and as summarized in
able 2, Ca2 transient and cell shortening in the cardio-
yocytes isolated from the pacing-induced failing dog hearts
ere deteriorated compared with those in normal cardiomyo-
ytes. Both Ca2 transient and cell shortening were partially
estored toward normal by the addition of dantrolene (1.0
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Diastolic Ca2 Spark and Ryanodine Receptor May 26, 2009:1993–2005mol/l). In normal cardiomyocytes, there was no detectable
hange in Ca2 transient and cell shortening after addition of
antrolene.
Because intracellular peak Ca2 transient strongly de-
ends on the SR Ca2 loading, we assessed SR Ca2
ontent by measuring peak Ca2 transient after the addi-
ion of caffeine. In normal cardiomyocytes, dantrolene was
ithout effect on peak Ca2 transient after the addition
f caffeine (Fig. 5B). In failing cardiomyocytes, peak
Figure 3 Effect of Dantrolene on SR Ca2 Leak
(A) Representative time courses of Ca2 uptake and Ca2 leak in normal and fail
Concentration dependence of dantrolene inhibition of the DPc10 (100 mol/l)-indu
inhibition on spontaneous Ca2 leak in failing SR vesicles. Each data point is a m
monophosphate (cAMP)-induced Ca2 leak in normal SR vesicles. Thapsigargin (0
pre-incubation of the SR vesicles with 30 mol/l cAMP plus 1 mol/l okadaic acida2 transient after the addition of caffeine was reduced, ohereas it was restored toward normal in the presence of
antrolene (1 mol/l) (Fig. 5C). These findings suggest
hat prevention of Ca2 leak by dantrolene is effective
o increase cardiomyocyte contractility by increasing SR
a2 loading.
To further explore the effects of dantrolene on the SR
a2 release mechanism, we investigated elementary
a2 release events (Ca2 sparks) in normal and failing
ardiomyocytes (Figs. 6A and 6B). In normal cardiomy-
rcoplasmic reticulum (SR) vesicles in the presence or absence of dantrolene. (B)
a2 leak in normal SR vesicles. (C) Concentration dependence of dantrolene
f 4 to 6 measurements  SD. (D) Effect of dantrolene on cyclic adenosine
l/l) was added after adenosine triphosphate-dependent Ca2 uptake after theing sa
ced C
ean o
.3 mo
.cytes, spontaneous Ca2 sparks occurred at a very low
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May 26, 2009:1993–2005 Diastolic Ca2 Spark and Ryanodine Receptorrequency. In DPc10-introduced cardiomyocytes, how-
ver, the frequency of spontaneous Ca2 sparks signifi-
antly increased, but it was reduced to a normal level in
he presence of dantrolene (1 mol/l). In cardiomyocytes
rom failing hearts, the spark frequency was markedly increased
Figure 4 Stern-Volmer Plots of the Fluorescence Quenching Da
(A) The Stern-Volmer plots of fluorescence quenching in the presence of various c
DPc10 to normal sarcoplasmic reticulum (SR). (B) Concentration dependence of d
mal SR. Note that dantrolene reduced the K=Q/KQ value (where K=Q is the quenchi
SR) in DPc10-added normal SR in a concentration-dependent manner (half-maxima
untreated normal SR. (C) The slope of Stern-Volmer plots of fluorescence quenchi
centration dependence of dantrolene inhibition of KQ/KQ (where KQ is the quench
SR. Note that dantrolene reduced on the KQ/KQ in failing SR in a concentration-de
ments  SD. BSA  bovine serum albumin.s in the DPc10-introduced normal cardiomyocyte, whereas ot decreased to a normal level in the presence of dantrolene
1 mol/l).
We further investigated the effect of dantrolene on the
embrane potential of isolated cardiomyocytes. In normal
ardiomyocytes, no fluctuation of membrane potential was
trations of dantrolene. Domain unzipping was produced by adding 100 mol/l
ne inhibition of domain unzipping (K=Q/KQ) in DPc10-added and untreated nor-
stant in DPc10-added normal SR and KQ is the quenching constant in normal
ition [IC50]  0.3 mol/l), whereas dantrolene had no appreciable effect in
a function of various concentrations of dantrolene added to failing SR. (D) Con-
nstant in failing SR and KQ is the quenching constant in normal SR) in failing
nt manner (IC50  0.3 mol/l). Each data point is a mean of 4 to 6 measure-ta
oncen
antrole
ng con
l inhib
ng as
ing co
pendebserved, even in the presence of 100 nmol/l forskolin after
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Diastolic Ca2 Spark and Ryanodine Receptor May 26, 2009:1993–2005Hz pacing (Fig. 7A), whereas the fluctuations of the mem-
rane potential, which seem to represent delayed afterdepo-
arization, were observed in the DPc10-incorporated cardio-
yocytes (Fig. 7A). However, the fluctuations of membrane
otential observed in the DPc10-incorporated cardiomyocytes
isappeared after the addition of dantrolene (Fig. 7A). As
hown in Figure 7B, the spontaneous fluctuations of mem-
rane potential were observed in failing cardiomyocytes,
hereas they were prevented from occurring in the presence of
antrolene (1 mol/l). The spontaneous fluctuations of mem-
rane potential observed in DPc10-incorporated or failing
Figure 5 Effect of Dantrolene on Ca2 Transient and Cell Short
(A) Ca2 transient and cell shortening in normal and failing cardiomyocytes in the
after the addition of caffeine in normal and failing cardiomyocytes. The caffeine-ind
was measured after a train of stimuli at 0.5 Hz by rapidly switching the perfusing
Ca2 transient after addition of caffeine (indicative of SR Ca2 load) was greater i
ameliorated the SR load by inhibiting SR Ca2 leak only in failing cardiomyocyte.ardiomyocytes were not induced by lower pacing rate (i.e., 1 tz; not shown) but induced only after the application of a
reater pacing rate (i.e., 3 Hz).
iscussion
efective interdomain interactions within RyR2 play a key
ole in the abnormal channel gating of RyR2 in failing
earts (6). Therefore, correction of the defective interdo-
ain interaction seems to be a new therapeutic strategy
gainst heart failure and possibly cardiac arrhythmia. In our
ecent reports (10,11), we have shown that both K201 and
nce or the absence of dantrolene (1.0 mol/l). (B) Ca2 transients before and
increase in Ca2 transients reflecting sarcoplasmic reticulum (SR) Ca2 load
n to the one containing 20 mmol/l caffeine for 5 to 6 s. Note that the peak
al cardiomyocyte than in failing cardiomyocyte and that dantrolene treatmentening
prese
uced
solutio
n normhe antioxidant edaravone prevent Ca2 leak through RyR2
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May 26, 2009:1993–2005 Diastolic Ca2 Spark and Ryanodine Receptory correcting the defective interdomain interaction within
yR2, in turn improving intracellular Ca2 handling and
ardiac function and attenuating LV remodeling during
evelopment of pacing-induced heart failure.
The most important aspect of the present study is the
nding that dantrolene, which might have been thought to
e a skeletal muscle-specific muscle relaxant, works on the
ardiac muscle as well. It is used to treat MH by correcting
efective interdomain interaction within RyR1. Dantrolene
s now found to bind to domain 601–620 of RyR2 and
orrect defective interdomain interaction within RyR2 in
ailing hearts. This action in turn inhibits spontaneous
a2 leak/Ca2 sparks and improves cardiomyocyte
unction in failing hearts. This conclusion is based on the
ollowing 6 findings. First, DPc10, which is the synthetic
eptide used as a domain switch unzipping agent, in-
uced domain unzipping (Figs. 4A and 4B). Both
Pc10-induced domain unzipping and the subsequent
a2 leak were inhibited by dantrolene. Dantrolene
nhibition of domain unzipping and that of Ca2 leak
howed an identical concentration dependence (IC50 
.3 mol/l) (Figs. 3 and 4). Second, in failing SR, the
yR is already in an unzipped state, as it occurs in normal
R after treatment with DPc10. Dantrolene restored the
ipped state in a concentration-dependent manner (IC50 
.3 mol/l) (Fig. 4D).
Similarly, dantrolene inhibited spontaneous Ca2 leak
rom failing SR with the same concentration dependence
IC50  0.3 mol/l) (Fig. 3C). Dantrolene also inhibited
he cAMP-induced Ca2 leak in normal SR. Third, the
ncorporation of DPc10 produced diastolic Ca2 sparks in
ormal cardiomyocytes, whereas these sparks were inhibited
y dantrolene. In failing cardiomyocytes, the magnitude of
he intracellular Ca2 transient decreased by 52% and its
ecay time was prolonged by 51%, but these abnormalities
ere normalized by 1 mol/l dantrolene.
Fourth, the SR Ca2 content, assessed by rapid applica-
ion of caffeine, was reduced in failing cardiomyocytes, but
t was restored by dantrolene, suggesting that the inhibition
f SR Ca2 leak by dantrolene increased SR Ca2 content
nd thereby improved Ca2 transient and cell shortening
Figs. 5A and 5B). Fifth, in the failing cardiomyocytes,
iastolic Ca2 sparks were observed, but they were elimi-
ffect of Dantrolene on Cell Shortening and Ca2 Transient in Norm
Table 2 Effect of Dantrolene on Cell Shortening and Ca2 Tran
No. of Cells Cell Shortening (%)
Normal (n  6)
Untreated 30 8.7 1.2
Dantrolene (1 mol/l) 30 8.6 2.3
Heart failure (n  4)
Untreated 30 1.7 0.5*
Dantrolene (1 mol/l) 38 5.8 2.6†
ell shortening: max % cell-length change from diastolic (baseline) level. Peak of Ca2 transient: m
umber of preparations is shown in parentheses. At least 4 cells were evaluated in each preparati
ersus untreated (normal). †p  0.01 versus untreated (heart failure).ated almost completely by 1 mol/l dantrolene. eSixth, importantly, 1 mol/l dantrolene had no appre-
iable effect on normal SR and cardiomyocyte functions in
ll experiments. It is also reported that dantrolene restores
ormal interdomain interactions within RyR1 (namely,
ipped state) in DP4-treated RyR1 channel, which is
nalogous to MH channel (8). Taken together, all of these
ata strongly suggest that the stable interdomain interaction
f regulatory domains within RyR1 or RyR2 is an essential
equirement for normal channel function. Defective inter-
omain interaction (namely, domain unzipping) causes
hannel dysfunction in RyR1 of MH and in RyR2 of failing
eart; thus, correction of the defective interdomain interac-
ion restores normal channel gating and hence prevents
iseased conditions.
Recently, Yang et al. (12) reported that DPc10 lowered
he [Ca2] threshold for spontaneous Ca2 release in
ermeabilized cardiomyocytes. That is, DPc10 mimicked
he abnormal channel gating seen in CPVT/ARVC2. Con-
istent with these data, abnormal diastolic Ca2 sparks were
bserved in DPc10-incorporated cardiomyocytes, while
antrolene suppressed the diastolic Ca2 sparks (Figs. 6A
nd 6B). Moreover, in DPc10-incorporated cardiomyo-
ytes, the fluctuation of membrane potential, which repre-
ents delayed afterdepolarization (DAD), was observed, and
antrolene prevented it from occurring (Fig. 7A). Thus, the
estoration of the domain interaction from defective un-
ipped state to normal zipped state by dantrolene may be a
ew strategy for the treatment of polymorphic VT and
ost-translationally developed heart failure as well.
Although it is widely recognized that dantrolene has an
ppreciable effect on RyR1, there is a controversy as to
hether dantrolene modulates channel gating of RyR2.
hao et al. (13) did not find any dantrolene inhibition of
a2 release in the RyR2 expressed in Chinese hamster
vary cells. In contrast, it is reported that dantrolene
mproved the inotropic response to norepinephrine in hu-
an failing heart (14) and reduced Ca2 oscillations,
hereby decreasing the magnitude of diastolic intracellular
Ca2] in post-infarcted rat myocardium (15).
The present finding that dantrolene inhibited cAMP-
nduced Ca2 leak may partly explain the improvement of
he beta-adrenergic responsiveness by dantrolene. Taken
ogether, dantrolene appears to have much more appreciable
d Failing Cardiomyocytes
in Normal and Failing Cardiomyocytes
k of Ca2 Transient (%) Time From Peak to 80% Decrease ( 102 s)
30.2 4.5 83.9 22.6
30.5 6.6 85.7 12.7
14.5 3.6* 126.9 18.9*
26.2 7.8† 99.2 16.9†
orescence change from diastolic (baseline) level. Each data point represents the mean SD. The
unpaired t test was used to determine the statistical significance of the data (p value). *p  0.01al an
sient
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Diastolic Ca2 Spark and Ryanodine Receptor May 26, 2009:1993–2005han in normal hearts because of its inhibition of diastolic
a2 release that can be seen only in failing hearts.
antrolene was found to enhance the Ca2 uptake rate in
at cardiac SR but also showed mild negative inotropic effect
n parallel with a decrease in peak Ca2 transient (16). In
hat study, however, the concentration of dantrolene was 50
mol/l, which is 50 times greater than that used in the
resent study. In the present study, dantrolene (0.1 to 1
mol/l) had no effect on the SR Ca2 uptake time course,
Figure 6 Effect of Dantrolene on Diastolic Ca2 Sparks in DPc10
(A) Representative line-scan images of Ca2 sparks. (B) Bar graphs summariz
mum (FWHM), full duration at half maximum (FDHM), for the same groups of c
group is 20 to 30.a2 transient, and cell shortening in normal hearts. Low eoncentrations of dantrolene (0.1 to 1 mol/l) used in this
tudy seem to have no significant effect on SR Ca2 ATPase
nd Ca2-induced Ca2 release in normal hearts.
The present data also showed that dantrolene inhibited
Pc10-induced Ca2 leak in normal RyR2 and spontane-
us Ca2 leak in failing RyR2, whereas it had no apprecia-
le effect on normal RyR2, in which interdomain interac-
ions between N-terminal and central regulatory domains
re still in the zipped state. These findings suggest that the
porated Normal Cardiomyocytes and in Failing Cardiomyocytes
various values on Ca2 spark: frequency, amplitude, full width at half maxi-
ach data point represents the mean  SD. The number of cells for each-Incor
e the
ells. Effect of dantrolene on channel gating depends on the
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May 26, 2009:1993–2005 Diastolic Ca2 Spark and Ryanodine Receptoronformational state of the regulatory domains. That is,
antrolene may be effective for stabilizing RyR2 only in the
nzipped state but not in the zipped state. The report that
3H]dantrolene-binding to the rabbit RyR2 could be seen
nly in particular conditions (in the presence of a very high
oncentration of ethylene glycol tetraacetic acid) (17) sup-
orts the idea that dantrolene binding to RyR2 is indeed
ependent on a particular conformational state of RyR2 that
akes place in disease conditions.
To identify the dantrolene binding site within the
yR2, we screened recombinant constructs correspond-
ng to the region from the N-terminus to the residue
Figure 7 Effect of Dantrolene on the Post-Pacing Fluctuation o
DAD in DPc10-Incorporated Normal Cardiomyocytes a
Pacing was performed at a greater pacing rate (3 Hz) in the presence of forskolin
potential were observed in DPc10-induced or failing cardiomyocytes but not in norm
normal cardiomyocytes (A) and in failing cardiomyocytes (B). DAD  delayed after750 by using the QCM assay and found that only the secombinant construct corresponding to aa494 –1000 and
he synthetic peptide corresponding to aa601– 620 bound
ith dantrolene. This finding indicates that the aa601–
20 region of RyR2 represents the site of dantrolene
inding. However, because our screening did not extend
eyond the residue 2750, we cannot exclude the possi-
ility that there might be another drug-binding region in
he carboxyl half of the RyR2. We also cannot exclude
he possibility that there might be additional drug-
inding sites, with a low affinity of binding, even in the
-terminal half, because some of the recombinant con-
tructs may have failed to retain the native tertiary
brane Potential
Failing Cardiomyocytes
mol/l) for a few seconds and stopped. Post-pacing fluctuation of the membrane
rdiomyocytes. Representative line-scan plots of membrane potential recorded in
rization.f Mem
nd in
(100 n
al ca
depolatructure required for high-affinity drug binding. Altered
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Diastolic Ca2 Spark and Ryanodine Receptor May 26, 2009:1993–2005ntracellular Ca2 handling is one of the causative mech-
nisms in the generation of lethal arrhythmia in the
atients with heart failure and CPVT. Diastolic Ca2
eak from SR via RyR2 will initiate DAD and triggered
ctivity, leading arrhythmia. Therefore, stabilization of
yR2 may be a novel therapeutic strategy against heart
ailure and CPVT (10). The proposed molecular mech-
nism by which dantrolene corrects the defective channel
ating in diseased RyR2 is summarized in the Figures 8A
nd 8B.
Figure 8 Schematic Illustration of the Effects of Dantrolene on
Intracellular Ca2 Handling and Membrane Potential i
(A) In normal cardiomyocytes, domain unzipping between the N-terminal and centr
Ca2 sparks. These Ca2 sparks subsequently induce the DAD caused by inward
abnormalities. (B) In failing cardiomyocytes, domain unzipping has already taken p
the Ca2 handling abnormalities. NCX  Na/Ca2 exchanger; other abbreviationonclusions
efective interactions of the regulatory domains in RyR2
eem to play a key role in the abnormal Ca2 channel
unctions of RyR2 found in the failing cardiomyocytes, such
s increased Ca2 spark frequency and DAD. The present
nding that the defective domain interaction is corrected by
antrolene provides one with a new clue for the develop-
ent of therapeutic strategy against heart failure and pos-
ibly lethal arrhythmia.
rmal
diomyocytes
ains occurs upon incorporation of DPc10, thereby causing aberrant diastolic
urrent via Na-Ca2 exchange. Dantrolene inhibits all of these Ca2 handling
and it induces aberrant diastolic Ca2 sparks and DAD. Dantrolene inhibits all of
Figures 3 and 7.Abno
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